Abnova's VHH nanoBiTE™ service focuses on developing bispecific VHH antibodies without an Fc domain, ideal for immune and tumor cell redirecting, multiple epitope targeting, and novel immuno-oncology research. Their smaller molecular size enhances tissue penetration, making them suitable for hard-to-access areas like the tumor microenvironment. The absence of an Fc region prevents unwanted immune activation by avoiding Fc receptor binding, supporting precise mechanistic action. Engineered through the genetic fusion of two VHH domains via a flexible peptide linker, VHH nanoBiTE™ ensures robust antigen binding with reduced production complexity.
Workflow |
Advantages |
- Small Size
- Superior Stability
- High Affinity and Specificity
- Easy Conjugation
- Enables Rapid Immune Cell Activation While Minimizing Systemic Exposure
- Cost-Effectiveness and Scalable Production
Examples |
Human PD-L1 x CD3e nanoBiTE™
Indirect ELISA |
Sandwich ELISA |
Flow cytometry |
- oem@abnova.com
- TW : +886-2-8751-1888 / USA : +1(857) 639 0367 / Korea : +82-1670-5911.